Disease severity predicts costs in age-related macular degeneration

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.403, 2003-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Burden of Age-Related Macular Degeneration

By Schmier Jordana K. Jones Mechelle L. Halpern Michael T.

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 319-334

Adis International

Access to resources Recommend Favorite

Pegaptanib: In Exudative Age-Related Macular Degeneration

By Siddiqui M. Asif A. Keating Gillian M.

Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. : 1571-1577

Adis International

Access to resources Recommend Favorite

By Lacour M.

Drugs & Aging, Vol. 19, Iss. 2, 2002-02 ,pp. : 101-133

Adis International

Access to resources Recommend Favorite

Prospective therapeutics for age-related macular degeneration

By Chiesa R.

Expert Opinion on Therapeutic Targets, Vol. 3, Iss. 4, 1999-12 ,pp. : 527-541

Informa Healthcare

Access to resources Recommend Favorite

An update on photodynamic therapy in age-related macular degeneration

By Rechtman Ehud Ciulla Thomas A Criswell Mark H Pollack Ayala Harris Alon

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 931-938

Informa Healthcare

Access to resources Recommend Favorite